Vaxcyte (PCVX) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- -$1.97
- Estimate
- -$2.10
- Surprise
- +6.1%
- Score today
- 5.4/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Vaxcyte (PCVX) reported a narrower loss than forecast — diluted EPS of -$1.97 against the -$2.10 estimate (a 6.1% beat on a still-unprofitable quarter).
Where TrendMatrix's rating stands now
TrendMatrix currently rates PCVX Sell at 5.4/10; no pre/post engine snapshot brackets this report.
1 of the last 4 quarters beat the estimate; this quarter's +6.1% surprise compares with a -17.4% four-quarter average. Next scheduled report: 2026-11-03.
What argues against it
- Concentration risk — Supplier: Sutro Biopharma
- Concentration risk — Supplier: Lonza
- Quality below floor (1.8 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $61.16
- Price target
- $94.83
- Stop
- $56.88
- Upside to target
- +55.1%
- Reward-to-risk
- 7.2:1
Model outputs from TrendMatrix’s engine as of 2026-09-05 — shown for context, not personalized investment advice.
PCVX at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $9.10B
- P/E (fwd)
- -8.5
- 52-week range
- $30.81–$65.00
- Off 52-week high
- 5.9%
- RSI (14)
- 54
- Volume vs avg
- 1.03×
- Score today
- 5.4/10